Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Endocrine Disorders
Published in: BMC Endocrine Disorders 1/2014

Open Access 01-12-2014 | Study protocol

Effect of dietary prebiotic supplementation on advanced glycation, insulin resistance and inflammatory biomarkers in adults with pre-diabetes: a study protocol for a double-blind placebo-controlled randomised crossover clinical trial

Authors: Nicole J Kellow, Melinda T Coughlan, Gayle S Savige, Christopher M Reid

Published in: BMC Endocrine Disorders | Issue 1/2014

Login to get access

Abstract

Background

Advanced glycation endproducts (AGEs) contribute to the development of vascular complications of diabetes and have been recently implicated in the pathogenesis of diabetes. Since AGEs are generated within foodstuffs upon food processing, it is increasingly recognised that the modern diet is replete with AGEs. AGEs are thought to stimulate chronic low-grade inflammation and promote oxidative stress and have been linked to the development of insulin resistance. Simple therapeutic strategies targeted at attenuating the progression of chronic low-grade inflammation and insulin resistance are urgently required to prevent or slow the development of type 2 diabetes in susceptible individuals. Dietary modulation of the human colonic microbiota has been shown to confer a number of health benefits to the host, but its effect on advanced glycation is unknown. The aim of this article is to describe the methodology of a double-blind placebo-controlled randomised crossover trial designed to determine the effect of 12 week consumption of a prebiotic dietary supplement on the advanced glycation pathway, insulin sensitivity and chronic low-grade inflammation in adults with pre-diabetes.

Methods/Design

Thirty adults with pre-diabetes (Impaired Glucose Tolerance or Impaired Fasting Glucose) aged between 40–60 years will be randomly assigned to receive either 10 grams of prebiotic (inulin/oligofructose) daily or 10 grams placebo (maltodextrin) daily for 12 weeks. After a 2-week washout period, study subjects will crossover to receive the alternative dietary treatment for 12 weeks. The primary outcome is the difference in markers of the advanced glycation pathway carboxymethyllysine (CML) and methylglyoxal (MG) between experimental and control treatments. Secondary outcomes include HbA1c, insulin sensitivity, lipid levels, blood pressure, serum glutathione, adiponectin, IL-6, E-selectin, myeloperoxidase, C-reactive protein, Toll-like Receptor 4 (TLR4), soluble receptor for AGE (sRAGE), urinary 8-isoprostanes, faecal bacterial composition and short chain fatty acid profile. Anthropometric measures including BMI and waist circumference will be collected in addition to comprehensive dietary and lifestyle data.

Discussion

Prebiotics which selectively stimulate the growth of beneficial bacteria in the human colon might offer protection against AGE-related pathology in people at risk of developing type 2 diabetes.

Trial registration

Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12613000130​763.
Appendix
Available only for authorised users
Literature
1.
Henle T: Protein-bound advanced glycation endproducts (AGEs) as bioactive amino acid derivatives in foods. Amino Acids. 2005, 29 (4): 313-322.PubMed
2.
Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature. 2001, 414 (6865): 813-820.PubMed
3.
Folli F, Corradi D, Fanti P, Davalli A, Paez A, Giaccari A, Perego C, Muscogiuri G: The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach. Curr Diabetes Rev. 2011, 7 (5): 313-324.PubMed
4.
Kotani K, Sakane N: C-reactive protein and reactive oxygen metabolites in subjects with metabolic syndrome. J Int Med Res. 2012, 40 (3): 1074-1081.PubMed
5.
Thornalley PJ: Dicarbonyl intermediates in the maillard reaction. Ann N Y Acad Sci. 2005, 1043: 111-117.PubMed
6.
Avery NC, Bailey AJ: The effects of the Maillard reaction on the physical properties and cell interactions of collagen. Pathol Biol. 2006, 54 (7): 387-395.PubMed
7.
Rosca MG, Mustata TG, Kinter MT, Ozdemir AM, Kern TS, Szweda LI, Brownlee M, Monnier VM, Weiss MF: Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am J Physiol Renal Physiol. 2005, 289 (2): F420-F430.PubMed
8.
Coughlan MT, Thorburn DR, Penfold SA, Laskowski A, Harcourt BE, Sourris KC, Tan AL, Fukami K, Thallas-Bonke V, Nawroth PP, Brownlee M, Bierhaus A, Cooper ME, Forbes JM: RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol. 2009, 20 (4): 742-752.PubMedPubMedCentral
9.
Yim MB, Yim HS, Lee C, Kang SO, Chock PB: Protein glycation: creation of catalytic sites for free radical generation. Ann N Y Acad Sci. 2001, 928: 48-53.PubMed
10.
Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D: Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest. 1995, 96 (3): 1395-1403.PubMedPubMedCentral
11.
Morita M, Yano S, Yamaguchi T, Sugimoto T: Advanced glycation end products-induced reactive oxygen species generation is partly through NF-kappa B activation in human aortic endothelial cells. J Diabetes Complications. 2013, 27 (1): 11-15.PubMed
12.
Tahara N, Yamagishi S, Matsui T, Takeuchi M, Nitta Y, Kodama N, Mizoguchi M, Imaizumi T: Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects. Cardiovasc Ther. 2012, 30 (1): 42-48.PubMed
13.
Tan KC, Shiu SW, Wong Y, Tam X: Serum advanced glycation end products (AGEs) are associated with insulin resistance. Diabetes Metab Res Rev. 2011, 27 (5): 488-492.PubMed
14.
Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H: Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann N Y Acad Sci. 2005, 1043: 461-466.PubMed
15.
Fiory F, Lombardi A, Miele C, Giudicelli J, Beguinot F, Van Obberghen E: Methylglyoxal impairs insulin signalling and insulin action on glucose-induced insulin secretion in the pancreatic beta cell line INS-1E. Diabetologia. 2011, 54 (11): 2941-2952.PubMed
16.
Coughlan MT, Yap FY, Tong DC, Andrikopoulos S, Gasser A, Thallas-Bonke V, Webster DE, Miyazaki J, Kay TW, Slattery RM, Kaye DM, Drew BG, Kingwell BA, Fourlanos S, Groop PH, Harrison LC, Knip M, Forbes JM: Advanced glycation end products are direct modulators of beta-cell function. Diabetes. 2011, 60 (10): 2523-2532.PubMedPubMedCentral
17.
Birlouez-Aragon I, Saavedra G, Tessier FJ, Galinier A, Ait-Ameur L, Lacoste F, Niamba CN, Alt N, Somoza V, Lecerf JM: A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases. Am J Clin Nutr. 2010, 91 (5): 1220-1226.PubMed
18.
Tessier FJ, Birlouez-Aragon I: Health effects of dietary Maillard reaction products: the results of ICARE and other studies. Amino Acids. 2012, 42 (4): 1119-1131.PubMed
19.
Sandu O, Song K, Cai W, Zheng F, Uribarri J, Vlassara H: Insulin resistance and type 2 diabetes in high-fat-fed mice are linked to high glycotoxin intake. Diabetes. 2005, 54 (8): 2314-2319.PubMed
20.
Cai W, Ramdas M, Zhu L, Chen X, Striker GE, Vlassara H: Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc Natl Acad Sci U S A. 2012, 109 (39): 15888-15893.PubMedPubMedCentral
21.
Uribarri J, Cai W, Ramdas M, Goodman S, Pyzik R, Chen X, Zhu L, Striker GE, Vlassara H: Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care. 2011, 34 (7): 1610-1616.PubMedPubMedCentral
22.
Mark AB, Poulsen MW, Andersen S, Andersen JM, Bak MJ, Ritz C, Holst JJ, Nielsen J, de Courten B, Dragsted LO, Bugel S: Consumption of a diet low in advanced glycation endproducts for 4 weeks improves insulin sensitivity in overweight women. Diabetes Care. 2014, 37 (1): 88-95.PubMed
23.
Luevano-Contreras C, Garay-Sevilla ME, Wrobel K, Malacara JM: Dietary advanced glycation end products restriction diminishes inflammation markers and oxidative stress in patients with type 2 diabetes mellitus. J Clin Biochem Nutr. 2013, 52 (1): 22-26.PubMed
24.
Harcourt BE, Sourris KC, Coughlan MT, Walker KZ, Dougherty SL, Andrikopoulos S, Morley AL, Thallas-Bonke V, Chand V, Penfold SA, de Courten MP, Thomas MC, Kingwell BA, Bierhaus A, Cooper ME, Courten B, Forbes JM: Targeted reduction of advanced glycation improves renal function in obesity. Kidney Int. 2011, 80 (2): 190-198.PubMed
25.
Kellow NJ, Savige GS: Dietary advanced glycation end-product restriction for the attenuation of insulin resistance, oxidative stress and endothelial dysfunction: a systematic review. Eur J Clin Nutr. 2013, 67 (3): 239-248.PubMed
26.
Round JL, Mazmanian SK: The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. 2009, 9 (5): 313-323.PubMedPubMedCentral
27.
Ding S, Chi MM, Scull BP, Rigby R, Schwerbrock NM, Magness S, Jobin C, Lund PK: High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse. PLoS One. 2010, 5 (8): e12191-PubMedPubMedCentral
28.
Diamant M, Blaak EE, de Vos WM: Do nutrient-gut-microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes?. Obes Rev. 2011, 12 (4): 272-281.PubMed
29.
Backhed F, Manchester JK, Semenkovich CF, Gordon JI: Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A. 2007, 104 (3): 979-984.PubMedPubMedCentral
30.
Hill MJ: Intestinal flora and endogenous vitamin synthesis. Eur J Cancer Prev. 1997, 6 (Suppl 1): S43-S45.PubMed
31.
Macfarlane GT, Macfarlane S: Fermentation in the human large intestine: its physiologic consequences and the potential contribution of prebiotics. J Clin Gastroenterol. 2011, 45 (Suppl): S120-S127.PubMed
32.
Wu X, Ma C, Han L, Nawaz M, Gao F, Zhang X, Yu P, Zhao C, Li L, Zhou A, Wang J, Moore JE, Millar BC, Xu J: Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr Microbiol. 2010, 61 (1): 69-78.PubMed
33.
Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK, Al-Soud WA, Sorensen SJ, Hansen LH, Jakobsen M: Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One. 2010, 5 (2): e9085-PubMedPubMedCentral
34.
Mills DJ, Tuohy KM, Booth J, Buck M, Crabbe MJ, Gibson GR, Ames JM: Dietary glycated protein modulates the colonic microbiota towards a more detrimental composition in ulcerative colitis patients and non-ulcerative colitis subjects. J Appl Microbiol. 2008, 105 (3): 706-714.PubMed
35.
Nakamura YK, Omaye ST: Metabolic diseases and pro- and prebiotics: mechanistic insights. Nutr Metab (Lond). 2012, 9 (1): 60-
36.
Quigley EM: Therapies aimed at the gut microbiota and inflammation: antibiotics, prebiotics, probiotics, synbiotics, anti-inflammatory therapies. Gastroenterol Clin North Am. 2011, 40 (1): 207-222.PubMed
37.
Delzenne NM, Neyrinck AM, Backhed F, Cani PD: Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Nat Rev Endocrinol. 2011, 7 (11): 639-646.PubMed
38.
Colagiuri SDD, Girgis S, Colagiuri R: National evidence based guideline for case detection and diagnosis of type 2 diabetes. 2009, Canberra, Australia: Diabetes Australia and the National Health and Medical Research Council
39.
Semba RD, Arab L, Sun K, Nicklett EJ, Ferrucci L: Fat mass is inversely associated with serum carboxymethyl-lysine, an advanced glycation end product, in adults. J Nutr. 2011, 141 (9): 1726-1730.PubMedPubMedCentral
40.
Kilhovd BK, Juutilainen A, Lehto S, Ronnemaa T, Torjesen PA, Hanssen KF, Laakso M: Increased serum levels of methylglyoxal-derived hydroimidazolone-AGE are associated with increased cardiovascular disease mortality in nondiabetic women. Atherosclerosis. 2009, 205 (2): 590-594.PubMed
41.
Lapolla A, Piarulli F, Sartore G, Ceriello A, Ragazzi E, Reitano R, Baccarin L, Laverda B, Fedele D: Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease. Diabetes Care. 2007, 30 (3): 670-676.PubMed
42.
Semba RD, Bandinelli S, Sun K, Guralnik JM, Ferrucci L: Plasma carboxymethyl-lysine, an advanced glycation end product, and all-cause and cardiovascular disease mortality in older community-dwelling adults. J Am Geriatr Soc. 2009, 57 (10): 1874-1880.PubMedPubMedCentral
43.
Kolida S, Meyer D, Gibson GR: A double-blind placebo-controlled study to establish the bifidogenic dose of inulin in healthy humans. Eur J Clin Nutr. 2007, 61 (10): 1189-1195.PubMed
44.
Causey JL: Effects of dietary inulin on serum lipids, blood glucose and the gastrointestinal environment in hypercholesterolemic men. Nutr Res. 2000, 20 (2): 191-201.
45.
Lecerf JM, Depeint F, Clerc E, Dugenet Y, Niamba CN, Rhazi L, Cayzeele A, Abdelnour G, Jaruga A, Younes H, Jacobs H, Lambrey G, Abdelnour AM, Pouillart PR: Xylo-oligosaccharide (XOS) in combination with inulin modulates both the intestinal environment and immune status in healthy subjects, while XOS alone only shows prebiotic properties. Br J Nutr. 2012, 108 (10): 1847-1858.PubMed
46.
Hull GLJ, Ames JM, Cuskelly GJ: NEpsilon-(carboxymethyl)lysine content of foods commonly consumed in a Western style diet. Food Chem. 2012, 131: 170-174.
47.
Bihuniak JD, Simpson CA, Sullivan RR, Caseria DM, Kerstetter JE, Insogna KL: Dietary protein-induced increases in urinary calcium are accompanied by similar increases in urinary nitrogen and urinary urea: a controlled clinical trial. J Acad Nutr Diet. 2013, 113 (3): 447-451.PubMed
48.
Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P: International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003, 35 (8): 1381-1395.PubMed
49.
Boehm BO, Schilling S, Rosinger S, Lang GE, Lang GK, Kientsch-Engel R, Stahl P: Elevated serum levels of N(epsilon)-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema. Diabetologia. 2004, 47 (8): 1376-1379.PubMed
50.
Zhang X, Frischmann M, Kientsch-Engel R, Steinmann K, Stopper H, Niwa T, Pischetsrieder M: Two immunochemical assays to measure advanced glycation end-products in serum from dialysis patients. Clin Chem Lab Med. 2005, 43 (5): 503-511.PubMed
51.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985, 28 (7): 412-419.PubMed
52.
Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M: Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000, 23 (1): 57-63.PubMed
53.
Matsuki T, Watanabe K, Fujimoto J, Miyamoto Y, Takada T, Matsumoto K, Oyaizu H, Tanaka R: Development of 16S rRNA-gene-targeted group-specific primers for the detection and identification of predominant bacteria in human feces. Appl Environ Microbiol. 2002, 68 (11): 5445-5451.PubMedPubMedCentral
54.
Dewulf EM, Cani PD, Claus SP, Fuentes S, Puylaert PG, Neyrinck AM, Bindels LB, de Vos WM, Gibson GR, Thissen JP, Delzenne NM: Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut. 2013, 62 (8): 1112-1121.PubMed
55.
Ramirez-Farias C, Slezak K, Fuller Z, Duncan A, Holtrop G, Louis P: Effect of inulin on the human gut microbiota: stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii. Br J Nutr. 2009, 101 (4): 541-550.PubMed
56.
Wang RF, Cao WW, Cerniglia CE: PCR detection and quantitation of predominant anaerobic bacteria in human and animal fecal samples. Appl Environ Microbiol. 1996, 62 (4): 1242-1247.PubMedPubMedCentral
57.
Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM, de Vos WM, Cani PD: Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A. 2013, 110 (22): 9066-9071.PubMedPubMedCentral
58.
Sebekova K, Boor P, Valachovicova M, Blazicek P, Parrak V, Babinska K, Heidland A, Krajcovicova-Kudlackova M: Association of metabolic syndrome risk factors with selected markers of oxidative status and microinflammation in healthy omnivores and vegetarians. Mol Nutr Food Res. 2006, 50 (9): 858-868.PubMed
59.
Vlassara H, Uribarri J, Cai W, Striker G: Advanced glycation end product homeostasis: exogenous oxidants and innate defenses. Ann N Y Acad Sci. 2008, 1126: 46-52.PubMed
60.
Goldberg T, Cai W, Peppa M, Dardaine V, Baliga BS, Uribarri J, Vlassara H: Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc. 2004, 104 (8): 1287-1291.PubMed
61.
Shen Q, Chen YA, Tuohy KM: A comparative in vitro investigation into the effects of cooked meats on the human faecal microbiota. Anaerobe. 2010, 16 (6): 572-577.PubMed
62.
Connolly ML, Lovegrove JA, Tuohy KM: In vitro fermentation characteristics of whole grain wheat flakes and the effect of toasting on prebiotic potential. J Med Food. 2012, 15 (1): 33-43.PubMed
63.
De Preter V, Hamer HM, Windey K, Verbeke K: The impact of pre- and/or probiotics on human colonic metabolism: does it affect human health?. Mol Nutr Food Res. 2011, 55 (1): 46-57.PubMed
64.
Faist V, Erbersdobler HF: Metabolic transit and in vivo effects of melanoidins and precursor compounds deriving from the Maillard reaction. Ann Nutr Metab. 2001, 45 (1): 1-12.PubMed
65.
Rapin JR, Wiernsperger N: Possible links between intestinal permeability and food processing: A potential therapeutic niche for glutamine. Clinics (Sao Paulo). 2010, 65 (6): 635-643.
66.
67.
Eun CS, Han DS, Lee SH, Paik CH, Chung YW, Lee J, Hahm JS: Attenuation of colonic inflammation by PPARgamma in intestinal epithelial cells: effect on Toll-like receptor pathway. Dig Dis Sci. 2006, 51 (4): 693-697.PubMed
68.
Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A: Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol. 2011, 17 (12): 1519-1528.PubMedPubMedCentral
69.
Delzenne NM, Cani PD: Interaction between obesity and the gut microbiota: relevance in nutrition. Annu Rev Nutr. 2011, 31: 15-31.PubMed
70.
Russo F, Linsalata M, Clemente C, Chiloiro M, Orlando A, Marconi E, Chimienti G, Riezzo G: Inulin-enriched pasta improves intestinal permeability and modifies the circulating levels of zonulin and glucagon-like peptide 2 in healthy young volunteers. Nutr Res. 2012, 32 (12): 940-946.PubMed
71.
Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, Muccioli GG, Delzenne NM: Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009, 58 (8): 1091-1103.PubMedPubMedCentral
72.
Cani PD: Crosstalk between the gut microbiota and the endocannabinoid system: impact on the gut barrier function and the adipose tissue. Clin Microbiol Infect. 2012, 18 (Suppl 4): 50-53.PubMed
73.
Schalkwijk CG, Miyata T: Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics. Amino Acids. 2012, 42 (4): 1193-1204.PubMed
74.
Anderson MM, Heinecke JW: Production of N(epsilon)-(carboxymethyl)lysine is impaired in mice deficient in NADPH oxidase: a role for phagocyte-derived oxidants in the formation of advanced glycation end products during inflammation. Diabetes. 2003, 52 (8): 2137-2143.PubMed
75.
Huebschmann AG, Regensteiner JG, Vlassara H, Reusch JE: Diabetes and advanced glycoxidation end products. Diabetes Care. 2006, 29 (6): 1420-1432.PubMed
76.
Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, Keilbaugh SA, Hamady M, Chen YY, Knight R, Ahima RS, Bushman F, Wu GD: High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology. 2009, 137 (5): 1716-1724. e1711-1712PubMedPubMedCentral
77.
Vrieze A, Holleman F, Zoetendal EG, de Vos WM, Hoekstra JB, Nieuwdorp M: The environment within: how gut microbiota may influence metabolism and body composition. Diabetologia. 2010, 53 (4): 606-613.PubMedPubMedCentral
78.
Esteve E, Ricart W, Fernandez-Real JM: Gut microbiota interactions with obesity, insulin resistance and type 2 diabetes: did gut microbiote co-evolve with insulin resistance?. Curr Opin Clin Nutr Metab Care. 2011, 14 (5): 483-490.PubMed
79.
Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, Waget A, Delmee E, Cousin B, Sulpice T, Chamontin B, Ferrieres J, Tanti JF, Gibson GR, Casteilla L, Delzenne NM, Alessi MC, Burcelin R: Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007, 56 (7): 1761-1772.PubMed
80.
Priebe MG, Wang H, Weening D, Schepers M, Preston T, Vonk RJ: Factors related to colonic fermentation of nondigestible carbohydrates of a previous evening meal increase tissue glucose uptake and moderate glucose-associated inflammation. Am J Clin Nutr. 2010, 91 (1): 90-97.PubMed
81.
Creely SJ, McTernan PG, Kusminski CM, Fisher FM, Da Silva NF, Khanolkar M, Evans M, Harte AL, Kumar S: Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab. 2007, 292 (3): E740-E747.PubMed
82.
Amar J: Energy intake is associated with endotoxemia induces adipose inflammation and insulin resistance in humans. Diabetes. 2010, 59: 9-
83.
Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, Gibson GR, Delzenne NM: Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007, 50 (11): 2374-2383.PubMed
84.
Lin MY, Yen CL: Inhibition of lipid peroxidation by Lactobacillus acidophilus and Bifidobacterium longum. J Agric Food Chem. 1999, 47 (9): 3661-3664.PubMed
85.
Yen CH, Kuo YW, Tseng YH, Lee MC, Chen HL: Beneficial effects of fructo-oligosaccharides supplementation on fecal bifidobacteria and index of peroxidation status in constipated nursing-home residents–a placebo-controlled, diet-controlled trial. Nutrition. 2011, 27 (3): 323-328.PubMed
86.
Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, Schilter HC, Rolph MS, Mackay F, Artis D, Xavier RJ, Teixeira MM, Mackay CR: Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature. 2009, 461 (7268): 1282-1286.PubMedPubMedCentral
87.
Vinolo MA, Rodrigues HG, Nachbar RT, Curi R: Regulation of inflammation by short chain fatty acids. Nutrients. 2011, 3 (10): 858-876.PubMedPubMedCentral
88.
Lewis K, Lutgendorff F, Phan V, Soderholm JD, Sherman PM, McKay DM: Enhanced translocation of bacteria across metabolically stressed epithelia is reduced by butyrate. Inflamm Bowel Dis. 2010, 16 (7): 1138-1148.PubMed
89.
Erridge C, Attina T, Spickett CM, Webb DJ: A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr. 2007, 86 (5): 1286-1292.PubMed
90.
Krogh-Madsen R, Plomgaard P, Akerstrom T, Moller K, Schmitz O, Pedersen BK: Effect of short-term intralipid infusion on the immune response during low-dose endotoxemia in humans. Am J Physiol Endocrinol Metab. 2008, 294 (2): E371-E379.PubMed
91.
Macia L, Thorburn AN, Binge LC, Marino E, Rogers KE, Maslowski KM, Vieira AT, Kranich J, Mackay CR: Microbial influences on epithelial integrity and immune function as a basis for inflammatory diseases. Immunol Rev. 2012, 245 (1): 164-176.PubMed
92.
Maslowski KM, Mackay CR: Diet, gut microbiota and immune responses. Nat Immunol. 2011, 12 (1): 5-9.PubMed
93.
Musso G, Gambino R, Cassader M: Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Annu Rev Med. 2011, 62: 361-380.PubMed
94.
Gugliucci A, Kotani K, Taing J, Matsuoka Y, Sano Y, Yoshimura M, Egawa K, Horikawa C, Kitagawa Y, Kiso Y, Kimura S, Sakane N: Short-term low calorie diet intervention reduces serum advanced glycation end products in healthy overweight or obese adults. Ann Nutr Metab. 2009, 54 (3): 197-201.PubMed
95.
Cani PD, Joly E, Horsmans Y, Delzenne NM: Oligofructose promotes satiety in healthy human: a pilot study. Eur J Clin Nutr. 2006, 60 (5): 567-572.PubMed
96.
Parnell JA, Reimer RA: Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am J Clin Nutr. 2009, 89 (6): 1751-1759.PubMed
97.
Ruijschop RBA, te Giffela MC: Satiety effects of a dairy beverage fermented with propionic acid bacteria. Int Dairy J. 2008, 18: 5-
98.
Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI: The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004, 101 (44): 15718-15723.PubMedPubMedCentral
99.
Aronsson L, Huang Y, Parini P, Korach-Andre M, Hakansson J, Gustafsson JA, Pettersson S, Arulampalam V, Rafter J: Decreased fat storage by Lactobacillus paracasei is associated with increased levels of angiopoietin-like 4 protein (ANGPTL4). PLoS One. 2010, 5 (9): doi:10.1371/journal.pone.0013087
100.
Dewulf EM, Cani PD, Neyrinck AM, Possemiers S, Van Holle A, Muccioli GG, Deldicque L, Bindels LB, Pachikian BD, Sohet FM, Mignolet E, Francaux M, Larondelle Y, Delzenne NM: Inulin-type fructans with prebiotic properties counteract GPR43 overexpression and PPARgamma-related adipogenesis in the white adipose tissue of high-fat diet-fed mice. J Nutr Biochem. 2011, 22 (8): 712-722.PubMed
101.
Vyas U, Ranganathan N: Probiotics, prebiotics, and synbiotics: gut and beyond. Gastroenterology Res Pract. 2012, 2012: 872716-
102.
Mehta R, Shangari N, O'Brien PJ: Preventing cell death induced by carbonyl stress, oxidative stress or mitochondrial toxins with vitamin B anti-AGE agents. Mol Nutr Food Res. 2008, 52 (3): 379-385.PubMed
103.
Stoyanova S, Geuns J, Hideg E, Van Den Ende W: The food additives inulin and stevioside counteract oxidative stress. Int J Food Sci Nutr. 2011, 62 (3): 207-214.PubMed
104.
Wu WT, Chen HL: Effects of konjac glucomannan on putative risk factors for colon carcinogenesis in rats fed a high-fat diet. J Agric Food Chem. 2011, 59 (3): 989-994.PubMed
105.
Todesco T, Rao AV, Bosello O, Jenkins DJ: Propionate lowers blood glucose and alters lipid metabolism in healthy subjects. Am J Clin Nutr. 1991, 54 (5): 860-865.PubMed
106.
Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, Cefalu WT, Ye J: Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes. 2009, 58 (7): 1509-1517.PubMedPubMedCentral
107.
Cani PD, Hoste S, Guiot Y, Delzenne NM: Dietary non-digestible carbohydrates promote L-cell differentiation in the proximal colon of rats. Br J Nutr. 2007, 98 (1): 32-37.PubMed
108.
Cani PD, Knauf C, Iglesias MA, Drucker DJ, Delzenne NM, Burcelin R: Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor. Diabetes. 2006, 55 (5): 1484-1490.PubMed
109.
Uchiki T, Weikel KA, Jiao W, Shang F, Caceres A, Pawlak D, Handa JT, Brownlee M, Nagaraj R, Taylor A: Glycation-altered proteolysis as a pathobiologic mechanism that links dietary glycemic index, aging, and age-related disease (in nondiabetics). Aging Cell. 2012, 11 (1): 1-13.PubMed
110.
Garcia AL, Otto B, Reich SC, Weickert MO, Steiniger J, Machowetz A, Rudovich NN, Mohlig M, Katz N, Speth M, Meuser F, Doerfer J, Zunft HJ, Pfeiffer AH, Koebnick C: Arabinoxylan consumption decreases postprandial serum glucose, serum insulin and plasma total ghrelin response in subjects with impaired glucose tolerance. Eur J Clin Nutr. 2007, 61 (3): 334-341.PubMed
111.
Lu ZX, Walker KZ, Muir JG, O'Dea K: Arabinoxylan fibre improves metabolic control in people with Type II diabetes. Eur J Clin Nutr. 2004, 58 (4): 621-628.PubMed
112.
Magliano DJ, Peeters A, Vos T, Sicree R, Shaw J, Sindall C, Haby M, Begg SJ, Zimmet PZ: Projecting the burden of diabetes in Australia–what is the size of the matter?. Aust N Z J Public Health. 2009, 33 (6): 540-543.PubMed
Metadata
Title
Effect of dietary prebiotic supplementation on advanced glycation, insulin resistance and inflammatory biomarkers in adults with pre-diabetes: a study protocol for a double-blind placebo-controlled randomised crossover clinical trial
Authors
Nicole J Kellow
Melinda T Coughlan
Gayle S Savige
Christopher M Reid
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2014
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/1472-6823-14-55

Other articles of this Issue 1/2014

BMC Endocrine Disorders 1/2014 Go to the issue

Research article

Anti-diabetic effect of a preparation of vitamins, minerals and trace elements in diabetic rats: a gender difference

Research article

Osteoporosis, vertebral fractures and metabolic syndrome in postmenopausal women

Research article

The association between improved quality diabetes indicators, health outcomes and costs: towards constructing a “business case” for quality of diabetes care - a time series study

Case report

Takotsubo cardiomyopathy and transient thyrotoxicosis during combination therapy with interferon-alpha and ribavirin for chronic hepatitis C

Research article

A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy

Study protocol

Study protocol: a randomised placebo-controlled clinical trial to s tu dy the effect of vitamin D supplemen tation on gly caemic control in type 2 Diabetes Mellitus SUNNY trial
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits